Basal cell carcinoma of skin
ICD-10 C44.9 · ICD-11 2C32

Treatment of Locally Advanced Basal Cell Carcinoma of Skin

This protocol addresses patients with locally advanced basal cell carcinoma of skin (laBCC) — a form of advanced BCC that warrants a defined, evidence-based treatment approach.

Clinical Scenario

Locally advanced basal cell carcinoma (laBCC) is a subset of advanced BCC. Advanced BCC encompasses both locally advanced disease (laBCC) and metastatic disease, each requiring its own management pathway.

Treatment Approach

The protocol for this scenario involves anti-PD1 immunotherapy — specifically the checkpoint inhibitor cemiplimab. Eligibility criteria, schedule, and full treatment parameters are detailed in the complete protocol…

Instant Access to Structured Evidence-Based Regimens

References

  1. Advanced BCC includes locally advanced BCC (laBCC) and metastatic BCC (mBCC).
  2. Anti-PD1 immunotherapy should be offered as second-line treatment in patients who progress or have contraindications to hedgehog inhibitors.
  3. Eighty-four laBCC patients received cemiplimab with the conventional dose of 350 mg intravenously every 3 weeks for up to 93 weeks or until progression or unacceptable toxicity.
DOI: 10.1016/j.ejca.2023.113254 View source ↗